On December 12th, the tenth batch of the national centralized procurement of pharmaceuticals was officially launched at 8:00 a.m. on the spot at No. 398, Zhanyuan Road, Nanqiao New Town, Fengxian District, Shanghai. This round of centralized procurement involved 62 varieties and 263 specifications, with both the number of involved enterprises and varieties reaching a record high. In this highly anticipated grand event in the pharmaceutical industry, Daoqun stood out among numerous competitors by virtue of its outstanding R&D strength, strict quality control, and excellent product performance. The 100mg Aspirin Enteric-coated Tablets independently developed by the group were shortlisted for the tenth batch of the national centralized procurement and were successfully selected, which is undoubtedly an important milestone in the development history of Daoqun.

Strength Forges Quality As a classic commonly used drug for antithrombotic treatment and prevention, Daoqun's 100mg Aspirin Enteric-coated Tablets embody the wisdom and painstaking efforts of Daoqun's scientific research team. From research and development to production, every link strictly adheres to high standards and strict requirements to ensure the quality and efficacy of the drugs. Its passing of the drug consistency evaluation fully demonstrates the consistency and equivalence of this drug with the original research drug in terms of quality and efficacy, providing patients with a reliable choice for medication. Classic Antithrombotic, Enteric-coated for Peace of Mind

Aspirin is a first-line antithrombotic drug recommended by authoritative domestic and foreign guidelines, and the enteric-coated formulation is safer with fewer incidents of gastrointestinal bleeding. Daoqun's 100mg Aspirin Enteric-coated Tablets are applicable to a variety of symptoms. They can reduce the risk of onset for patients suspected of having acute myocardial infarction; prevent the recurrence of myocardial infarction and secondary prevention of stroke; reduce the risk of transient ischemic attack (TIA) and its secondary stroke; reduce the risk of onset for patients with stable and unstable angina pectoris; after arterial surgical operations or interventional procedures, such as percutaneous transluminal coronary angioplasty (PTCA), coronary artery bypass grafting (CABG), carotid endarterectomy, arteriovenous shunt; prevent deep vein thrombosis and pulmonary embolism after major surgeries; reduce the risk of myocardial infarction for those with cardiovascular risk factors (family history of coronary heart disease, diabetes, dyslipidemia, hypertension, obesity, smoking history, those over 50 years old). The Significance of Centralized Procurement Is Great and the Market Prospects Are Broad The successful selection in this national centralized procurement is not only a high recognition of Daoqun Pharmaceutical but also great news for the vast number of patients. With the implementation of the centralized procurement policy, Daoqun's 100mg Aspirin Enteric-coated Tablets will benefit more patients with more favorable prices and wider coverage, effectively alleviating the burden of patients' medication, improving the accessibility and compliance of patients' medication, and contributing more to the prevention and treatment of cardiovascular and cerebrovascular diseases. Sales Situation of Aspirin Enteric-coated Tablets in National Grade Hospitals

Sales Situation of Aspirin Enteric-coated Tablets in National Grade Hospitals

Data Source: Zhongkang KESI System

According to the data from Zhongkang KESI, the annual sales volume of Aspirin Enteric-coated Tablets in the domestic market exceeds 3.2 billion yuan, and it occupies an important position in the national grade hospitals and the retail market. Moreover, with the intensification of the aging population in China, the number of patients with cardiovascular and cerebrovascular diseases is constantly increasing, the market scale of antithrombotic drugs continues to expand, and the market demand for Aspirin Enteric-coated Tablets will further grow. The successful selection of Daoqun's 100mg Aspirin Enteric-coated Tablets will enable it to occupy a favorable position in this broad market and is expected to achieve a significant increase in market share, laying a solid foundation for the sustainable development of the enterprise. Daoqun Group will take the successful selection in this national centralized procurement as an opportunity, continue to uphold the concept of "Assisting in Medical Treatment and Guarding Health", increase investment in R&D, continuously improve product quality and technological innovation ability, launch more high-quality, efficient, and safe pharmaceutical products, and contribute more to promoting the development of China's pharmaceutical cause. Meanwhile, Daoqun will also actively fulfill its social responsibilities, pay attention to the needs of patients, and make unremitting efforts to improve the health level of the whole nation. Once again, congratulations on the successful selection of Daoqun's 100mg Aspirin Enteric-coated Tablets in the tenth batch of the national centralized procurement! Let's look forward to Daoqun Pharmaceutical creating more brilliant achievements in the future and making greater contributions to the cause of human health.